126
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Ischaemia modified albumin in patients with acute coronary syndrome and negative cardiac troponin I

, , , , &
Pages 130-134 | Received 29 Dec 2011, Accepted 29 Nov 2012, Published online: 17 Jan 2013
 

Abstract

Background. Approximately 40–60% of patients with acute coronary syndrome (ACS) have normal cardiac troponin I (cTnI) concentrations on admission. Ischaemia modified albumin (IMA) has been suggested as a new biomarker of myocardial ischaemia. Methods. A total of 43 patients presenting with symptoms suggestive of ACS but with normal (< 0.1 μg/L) cTnI concentrations and 45 healthy subjects were studied. The patients from the study group were divided into two groups: STEMI (n = 28) and NSTEMI (n = 15). All these patients were undergoing percutaneous coronary intervention (PCI) with stenting. The concentrations of cTnI, myoglobin and IMA were determined on admission and 4 h after PCI. Results. Mean (SD) IMA concentrations were higher in patients with ACS (114.39 ± 25.18 U/ml) as compared to the control group (96.24 ± 6.28 U/ml, p < 0.005). IMA concentrations ≥ 104.0 U/ml demonstrated 72.1% sensitivity and 75.6% specificity for the diagnosis of ACS. The area under the receiver operator characteristic curve was 0.766 (95% CI 0.664–0.868) for ACS patients (NSTEMI + STEMI). In both groups increased median (IQR) cTnI concentration after PCI was observed (STEMI patients to 65.4 (10.9–106.9) μg/L and NSTEMI to 17.6 (0.77–84.0) μg/L). In contrast, no increase in IMA concentration was observed. Conclusions. IMA may be a useful biomarker for the identification of ACS patients presenting with typical acute chest pain and/or abnormal electrocardiograms but negative cTnI.

Acknowledgements

We thank Dr D. Rabczenko for his advice on the statistical evaluation of our data.

Declaration of interest: Drs Sygitowicz and Sitkiewicz have received speaker's honoraria from Siemens Healthcare – Poland, and Dr Sitkiewicz from Roche Diagnostics. The other authors have no conflicts of interest to declare.

This work was supported by grant No 2.34/II/01 from the National Institute of Cardiology – Warsaw, Poland.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.